Epstein-Barr virus - Epidemiological, biomolecular and transplantological aspects;Charakterystyka wirusa Epsteina-Barr - Aspekty epidemiologiczne, biomolekularne i transplantologiczne

Postepy Mikrobiologii

Volumn 46, Issue 2, 2007, Pages 153-165

  Bienias, Joanna ^a   Krzemień, Sławomira ^a   Mazurek, Urszula ^b  

^a Katedra I Klinika Hematologii I Transplantacji Szpiku la skiej AM W Katowicach   (Poland)

^b Katedra I Zaklład Biologii Molekularnej I Genetyki Medycznej Śla̧skiej AM ^*  (Poland)

Author keywords

Epstein Barr virus; Genome; Infection; Transplantology

Indexed keywords

B LYMPHOCYTE; BIOMOLECULAR ELECTRONICS; BURKITT LYMPHOMA; CELLULAR IMMUNODEFICIENCY; DUNCAN DISEASE; EPIDEMIOLOGICAL DATA; EPSTEIN BARR VIRUS; GENOME; HODGKIN DISEASE; HUMAN; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; MONONUCLEOSIS; NASOPHARYNX CARCINOMA; NATURAL KILLER CELL; NONHUMAN; REVIEW; TRANSPLANTATION;

HUMAN HERPESVIRUS 4;

EID: 34547169493     PISSN: 00794252     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Anagnostopoulos I., Hummel M.: Epstein-Barr virus in tumours. Histopath. 29, 297-315 (1996)
2. Ayumi K., Masatoshi F., Tohru K., Kiyotaka K., Yutaka S., Shunji I., Yukihiro N., Tatsuya T.: Reactivation of lytic replication from B cells latently infected with Epstein-Barr virus occurs with S-phase cyclin-dependent kinase activity while inhibiting cellular DNA replication. J. Virol. 77, 851-861 (2003)
3. Bartkowiak J.: Badania molekularne w rozpoznaniu i róż nicowaniu chorób zakaźnych. Przegl. Epid. 57, 381-389 (2003)
4. Benkerrou M., Jais J., Leblond V., Durandy A., Sutton L., Bordigoni P., Gamier J., Bidois J., Deist F., Blanche S., Fischer A.: Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood, 92, 3137-3147 (1998)
5. Bieńkowska-Szewczyk K.: Synteza glikoprotein herpesvirusowych w systemie bakulowirusowym - zastosowanie praktyczne i badawcze. Post. Mikrobiol. 41, 199-225 (2002)
6. Bober G., Krawczyk-Kuliś M., Kopera M., Hołowiecki J.: Ciȩżka izolowana małopłytkowość w przebiegu jednoczesnej infekcji wirusem cytomegalii i Epsteina-Barr u chorej bez upośledzenia odporności. Pol. Arch. Med. Wew. 109, 623-627 (2003)
7. Bryant H., Farrell P.: Signal transduction and transcription factor modification during reactivation of Epstein-Barr virus from latency. J. Virol. 76, 10290-10298 (2002)
8. Carpentier L., Tapiero B., Alvarez F., Viau C., Alfieri C.: Epstein-Barr virus (EBV) early - antigen serologic testing in conjunction with periferial blood EBV DNA load as a marker for risk of posttransplantation lymphoproliferative disease. J. Infect. Dis. 188, 1853-1864 (2003)
9. Chiang K., Hazlett L., Godder K., Abhyankar S., Christiansen N., van Rhee F., Lee C., Bridges K., Parrish R., Henslee-Downey P.: Epstein-Barr virus-associated B cell lymphoproliferative disorders following mismatched related T cell-depleted bone marrow transplantation. Bone Marrow Transpl. 28, 1117-1123 (2001)
10. Clavies A., Tiemann M., Wagner H-J., Dreger P., Suttorp M.: Epstein-Barr virus-associated post-transplant lymphoproliferative disease after bone marrow transplantation mimicking graft-versus-host disease. Pediatr. Transplant. 4, 151-155 (2000)
11. Cooper L., Longnecker R.: Inhibition of host kinase activity altered by the LMP2A signalosome-a therapeutic target for Epstein-Barr virus latency and associated disease. Antiviral Res. 56, 219-231 (2002)
12. Danve C., Decaussin G., Gusson P., Ooka T.: Growth transformation of primary epithelial cells a NPC-derived Epstein-Barr virus strain. Virology, 228, 223-235 (2001)
13. Dawson C., Dawson J., Jones R., Ward K., Young L.: Functional differences between BHRF1, the Epstein-Barr Virus-Encoded Bcl-2 homologue, and Bcl-2 in human epithelial cells. J. Virol. 72, 9016-9024 (1998)
14. Dȩbińska-Kieć A., Naskalski J.: Diagnostyka laboratoryjna z elementami biochemii klinicznej. Wyd. Med. Urban i Partner, Wrocław 2002, 95-134
15. Dharnidharka W., Douglas V., Hunger S., Fennel R.: Hodgkin's lymphoma after post-transplant lymphoproliferative disease in renal transplant recipients. Pediatr. Transpl. 8, 87-90 (2004)
16. Dunphy C., Galambos C., Polski J., Evans H., Gardner L., Grosso L., Montone K.: Extranodal posttransplant plasmacytic hyperplasia with subsequent posttransplant plasmacytic malignancy: six-year interval case report and review of the literature. Arch. Pathol. Lab. Med. 126, 351-356 (2002)
17. Dunphy C., Gardner L., Groso L., Evans L.: Flow cytometric immunophenotyping in posttranspjant lymphoproliferative disorders. Am. J. Clin. Pathol. 117, 24-28 (2002)
18. Fielding C., Sandvej K., Mehl A., Brennan P., Jones M., Rowe M.: Epstein-Barr Virus LMP-1 natural sequence variants differ in their potential to activate cellular signaling pathways. J. Virol. 75, 9129-9141 (2001)
19. Gartner BC., Schafer H., Marggraff K., Eisele G., Schafer M., Dilloo D., Roemer K., Laws H., Sester M., Sester U., Einsele H., Mueller-Lantzsch N.: Evaluation of use of Epstein-Barr viral load in patient after allogenic stem cell transplantation to diagnose and monitor post transplant lymphoproliferative disease. J. Clin. Microbiol. 40, 351-358 (2002)
20. Glaser S., Gulley M., Borowitz M., Craig F., Mann R., Steward S., Shema S., Ambinder R.: Inter- and intra-observer reliability of Epstein-Barr virus detection in Hodgkin Lymphoma using histochemical procedures. Leuk. Lymph. 45, 489-497 (2004)
21. Glenna B. Winnie: Mononucleosis and Epstein-Barr virus infection. eMedicine, http://www.emedicine.com/PED/topic705.htm (2002). Data ostatniego sprawdzenia 27.03.2007
22. Gordadze A., Poston D., Ling P.: The EBNA2 Polyproline region is dispensable for Epstein-Barr virus-mediated immortalization maintenance. J. Virol. 76, 7349-7355 (2002)
23. Gradoville L., Kwa D., El-Guindy A., Miller G.: Protein kinase c-independent activation of the Epstein-Barr virus lytic cycle. J. Virol. 76, 5612-5626 (2002)
24. Gulley M., Swinnen L., Plaisance K., Schnell C., Grogan T, Schneider B.: Tumor origin and CD20 expression in post-transplant lymphoporliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy. Transplant. 76, 959-964 (2003)
25. Gustafsson A., Levitsky V., Zou J., Frisan T., Dalianis T., Ljungman P., Ringden O., Winiarski J., Ernberg I., Masucci M.: Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood, 95, 807-814 (2000)
26. Heath JA., Broxson EH., Dole MG., Filippa DA., George D., Lyden D., Dunkel IJ.: Epstein-Barr virus-associated lymphoma in child undergonig an autologus stem cell rescue. J. Pediatr. Hematol. Oncol. 24, 160-163 (2002)
27. Hecht J., Cibas E., Kutok J.: Fine-needle aspiration cytology of lymphoproliferative disorders in the immunsuppressed patient: the diagnostic utility of in situ hybridization for Epstein-Barr virus. Diagn. Cytopathol. 26, 360-365 (2002)
28. Ho DL., Byrnes WM., Ma WP., Shi Y. Callaway DJ., Bu Z.: Structure-specific DNA induced conformational changes in Taq polymerase revealed by small angle neutron scattering. J. Biol. Chem. 279, 39146-39154 (2004)
29. Huang Q., Petros A., Wirgin H., Fesik S., Olejniczak W.: Solution structure of the BHRF-1 protein from Epstein-Barr virus, a homolog of human Bcl-2. J. Mol. Biol. 332, 1123-1130 (2003)
30. Janeczko J.: Mononukleoza zakaźna. Przegl. Epidemiol. 55, 421-431 (2001)
31. Jarrett R.: Risk factors for Hodgkin's lymphoma by EBV, status and significance of detection of EBV genomes in serum of patients with EBV-associated Hodgkin's lymphoma. Leuk. Lymph. 44, 27-32 (2003)
32. Jiang H., Cho Y., Wang F.: Structural, functional, and genetic comparisons of Epstein-Barr virus nuclear antigen 3A, 3B, and 3C homologues encoded by the Rhesus Lymphocryptovirus. J. Virol. 74, 5921-5932 (2000)
33. Keating S., Prince S., Jones M., Rowe M.: The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules. J. Virol. 76, 8179-8188 (2002)
34. Kirschner A., Omerovic J., Popov B., Longnecker R., Jardetzky T.: Soluble Epstein-Barr virus glycoproteins gH, gL, and gp2 form a 1:1:1 stable complex that acts like soluble gp42 in B-cell fusion but not in epithelial cell fusion. J. Virol. 80, 9444-9454 (2006)
35. Knipe D., Howley P., Griffin D.: Field's virology. Lippincott Wiliams & Wilkins, Philadelphia, 2001, s. 2343-2381
36. Kojima M., Yamane Y., Itoh. H., Tanaka H., Sugigara S., Masawa N., Nakamura S.: Epstein-Barr virus-related lymph node lesion resembling autoimmune disease-like clinicopathological findings in elderly patient. Report of three cases. APMIS, 111, 1083-1088 (2003)
37. Kosz-Vnenchak M., Wicher K.: Mechanizmy latencji wybranych wirusów z rodziny Herpesviridae. Post. Mikrobiol. 38, 5-39 (1999)
38. Lee M., Diamond M., Yates J.: Genetic evidence that EBNA-1 is needed to efficient stable latent infection by Epstein-Barr virus. J. Virol. 73, 2974-2982 (1999)
39. Lewis G. Molecular biology support unit. Quantitative PCR technologies. Cardiff University. (2003) http://www.cf.ac.uk/ biosi/research/molbiol/Quantpcr/ Data ostatniego sprawdzania: 27.03.2007
40. Lixin Y., Seiji M., Kenzo T.: CD 21-mediated entry and stable infection by Epstein-Barr Vims in canine and rat cells. J. Virol. 74, 10745-10751 (2000)
41. Marechal V., Dehee A., Chikhi-Brachet R., Piolot T., Coppey-Moisan M., Nicolas J.: Mapping EBNA-1 domains involved in binding to metaphase chromosomes. J. Virol. 73, 4385-4392 (1999)
42. Marshall W., Yim C., Gustafson E., Graf T., Sage D., Hanify K., Williams L., Fingeroth J., Finberg R.: Epstein-Barr virus encodes a novel homolog of the bcl-2 oncogene that inhibits apoptosis and associates with bax and bak J. Virol. 73 5181-5185 (1999)
43. Masy E., Coll J. i wsp.: Human monocytic cell lines transformed in vitro by Epstein-Barr virus display a type II latency and LMP-1-dependent proliferation. J. Virol. 76, 6460-6472 (2002)
44. Matsuda G., Nakajima K., Kawaguchi Y., Yamanashi Y., Hirai K.: Epstein-Barr virus (EBV) nuclear antigen leader protein (EBNA-LP) forms complexes with a cellular anti-apoptosis protein Bcl-2 or its EBV counterpart BHRF1 through HS1-associated protein X-1. Microbiol. Immunol. 4, 91-99 (2003)
45. Meerbach A., Gruhn B., Egerer R., Reischl U., Zintl F., Wutzler P.: Semiquantitative PCR analysis of Epstein-Barr virus DNA in clinical samples of patients with EBV-associated disease. J. Med. Virol. 65, 348-357 (2001)
46. Mentzer S., Perrine S., Faller D.: Epstein-Barr virus posttransplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate. Transpl. Infect. Dis. 3, 177-85 (2001)
47. Murray P., Young L: Epstein-Barr virus infection: basis on malignancy and potential for therapy. (2001) http://www-ermm.cbcu.cam.ac.uk/01003842h.htm. Data ostatniego sprawdzenia: 27.03.2007 r.
48. Nalesnik M., Demetris A, Fung J., MD, Randhawa P., MD, Zeevi A., PTLD Posttransplantation Lymphoproliferative Disorders. http://www.medscape. com/viewprogram/324 Data ostatniego sprawdzania: 27.03.2007 r.
49. Niemiałtowski M.: Aktywność cytotoksyczna efektorowych limfocytów T w ostrych i persystentnych/latentnych zakażeniach herpeswirusowych i HIV: testament zakażonej komórki. Post. Mikrobiol. 38, 355-381 (1999)
50. Niesters H.G.M.: Molecular and diagnostic clinical virology in real time. Clin. Microbiol. Inf. 10, 5-11 (2004)
51. O'Leary J., Engels K., Dada M.: The polymerase chain reaction in pathology. J. Clin. Pathol. 50, 805-810 (1997)
52. Ohga S., Kanaya Y., Maki H., Takada H., Ohshima K., Kanda M., Nomura A., Suminoe A., Matsuzaki A., Hara T.: Epstein-Barr virus-associated lymphorpoliferative disease after a cord blood transplant for Diamond-Blackfan anemia. Bone Marrow Transpl. 25, 209-212 (2000).
53. Olejnik A.: Herpeswirusy (Herpesviridae). (w:) Wirusologia Lekarska , red. Goździcka-Józefiak A. Wyd. Nauk. Uniw. im A. Mickiewicza, Poznań, 2004, s. 93-102
54. Oshima K., Muta K., Nakashima M., Haraoka S., Tutiya T., Suzumiya J., Kasaki C., Wetanabe T., Kikuchi M.: Expression of human tumor-associated antigen RCAS1 in Reed-Sternberg cells in association with Epstein-Barr virus infection: a potential mechanism of immune evasion. Int. J. Cancer. 93, 91-96 (2001)
55. Prince S., Keating S., Fielding C., Brennan P., Floettmann E., Rowe M.: Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms. J. Virol. 77, 5000-5007 (2003)
56. Raut A., Huryn J., Pollack A., Zlotolow I.: Unusual gingival presentation of post-transplantation lymphoproliferative disorder: a case report and review of the literature. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 90, 436-441 (2000)
57. Read-Connole E.: Vims replication and immune responses to infection. (2002) http://www.medscape.com/viewarticle/440153 Data ostatniego sprawdzenia adresu 27.03.2007 r.
58. Rivailler P., Cho Y., Wang F.: Complete genomic sequence of an Epstein-Barr virus-related Herpesvirus naturally infecting a new world primate: a defining point in the evolution of oncogenic Lymphocryptovirases. J. Virol. 76, 12055-12068 (2002)
59. Robertson P; Beynon S; Whybin R; Brennan C; Vollmer-Conna U; Hickie I; Lloyd A. Measurement of EBV-IgG anti-VCA avidity aids the early and reliable diagnosis of primary EBV infection. J. Med. Virol. 70, 617-623 (2003)
60. Rudzki Z., Werda L., Pia̧tkowska-Jakubas B., Mensah P., Zazula M., Białas M., Skotnicki A., Stachura J.: Fatal posttransplant lymphoproliferative disorder following allogenic bone marrow transplantation for aplastic anemia. Pol. J. Pathol. 53, 35-40 (2002)
61. Ruf I., Moghaddam A., Wang F. Sample J.: Mechanisms that regulate Epstein-Barr virus EBNA-1 gene transcription during restricted latency are conserved among Lymphocryptoviruses of Old World Primates. J. Virol. 73, 1980-1989 (1999)
62. Rulf I., Rhyne P., Yang Ch., Cleveland J., Sample J.: Epstein-Barr virus small RNAs potentate tumurogenicy of Burkitt Lymphoma cells independently of effect on apoptosis. J. Virol. 74, 10223-10228 (2000)
63. Sandberg M., Kaykas A., Sugden B.: Latent membrane protein 1 of Epstein-Barr virus inhibits as well as stimulates gene expression. J. Virol. 74, 9755-9761 (2000)
64. Schafer H., Berger C., Aepinus C., Hebart H., Beck R., Kaiserling E., Kanz L., Eomsele H., Knecht H.: Molecular pathogenesis of Epstein-Barr virus associated posttransplant lymphomas: new insights through latent membrane protein 1 fingerprint. Transplant. 72, 492-496 (2001)
65. Sheppard C, Cohen B, Andrews N. i wsp.: Development and evaluation of an antibody capture ELISA for detection of IgG to Epstein-Barr virus in oral fluid samples. J. Virol. Meth. (Netherlands), 93, 157-166 (2001)
66. Shosuke I., Jun N., Kenzo T.: Cell-to-cell contact as an efficient mode of Epstein-Barr Vims infection of diverse human epithelial cells. J. Virol. 72, 4371-4378 (1998)
67. Simon K., Dziemianko I.: Obraz kliniczny zakażeń Herpes-viridae w stanach obniżonej odporności - u chorych po przeszczepach szpiku kostnego i narza̧dów mia̧ższowych. Przegl. Epidemiol. 58, 289-297 (2003).
68. Swinnen L.J.: Diagnosis and treatment of transplant-related lymphoma. Ann. Oncol. 11, 45-48 (2000)
69. Takahara M., Kishibe K., Bandoh N., Nonaka S., Harabuchi Y.: Clinicopathologic and genetic studies of nasal NK/T-cell lymphoma - 1. Clinical features and prognosis. Int. Congress Series, 1240, 1137-1140 (2003)
70. Witkowska-Vogtt E.: Klinika i diagnostyka zakażeń wirusem Epsteina-Barr (EBV). Przegl. Epidemiol. 56, 25-33 (2002)
71. Yabe M., Yabe H., Hattori K., Shimizu T., Matsumoto M., Morimoto T., Yasuda Y., Inoue H., Kato S., Nishimura T. Role of interleukin-12 in the development of acute graft-versus-host disease in bone marrow transplant patients. Bone Marrow Transp. 24, 29-34 (1999)
72. Zawilińska B., Gruszka K., Pia̧tkowska-Jakubas B., Garlicki M., Skotnicki A.: Zakażenie wirusem Epsteina-Barr u pacjentów po przeszczepie szpiku kostnego i serca. Przegl. Epidemiol. 55, 52-55 (2001)
73. Zhang L., Pagano JS.: Interferon regulatory factor 7: a key cellular mediator of LMP-1 in EBV latency and transformation. Semin. Cancer Biol. 11, 445-453 (2001)
74. Żuk A.: Syntetyczne inhibitory replikacji Herpesvirusów - metody badania aktywności in vitro. Post. Mikrobiol. 42, 87-104 (2003)